This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Apollo Endosurgery Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Chas McKhann

İcra Kurulu Başkanı

US$2.8m

Toplam tazminat

CEO maaş yüzdesi	19.8%
CEO görev süresi	2.1yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	5.2yrs

Son yönetim güncellemeleri

Recent updates

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Mar 03

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Feb 10

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Jan 31

Assessing Apollo Endosurgery

Dec 27

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Dec 27

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Dec 01

Apollo Endosurgery EPS beats by $0.10, beats on revenue

Nov 05

CEO Tazminat Analizi

Chas McKhann'un ücretlendirmesi Apollo Endosurgery'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2022	US$3m	US$550k	-US$40m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$9m	US$375k	-US$25m

Tazminat ve Piyasa: Chas's total compensation ($USD2.78M) is about average for companies of similar size in the US market ($USD2.67M).

Tazminat ve Kazançlar: Chas's compensation has been consistent with company performance over the past year.

CEO

Chas McKhann (53 yo)

2.1yrs

Görev süresi

US$2,780,544

Tazminat

Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.2m
Jeffrey Black	CFO, Secretary & Treasurer	1.7yrs	US$1.34m	0.18% $ 1.0m
John Molesphini	Executive Vice President of Operations	5yrs	US$662.23k	0.079% $ 460.8k
Sergey Kantsevoy	Co-Founder and Innovation Partner	no data	Veri yok	Veri yok
Anthony Kalloo	Co-Founder and Innovation Partner	no data	Veri yok	Veri yok
Robert Hawes	Co-Founder and Innovation Partner	no data	Veri yok	Veri yok
Peter Cotton	Co-Founder and Innovation Partner	18.3yrs	Veri yok	Veri yok
Christopher Gostout	Co-Founder & Chief Medical Officer	no data	US$1.16m	0.062% $ 361.2k
Sydney Chung	Co-Founder and Innovation Partner	no data	Veri yok	Veri yok
Pankaj Pasricha	Co-Founder	18.3yrs	Veri yok	Veri yok
John Gillings	Investor Relations Manager	no data	Veri yok	Veri yok
Brian Szymczak	Vice President of Legal & Compliance	3.6yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: APEN's management team is considered experienced (4.3 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.2m
John Barr	Independent Chairman of the Board	4.1yrs	US$193.24k	0.051% $ 298.6k
Julie Shimer	Independent Director	4.9yrs	US$164.49k	0.038% $ 218.0k
Richard McGaughy	Independent Director	11.3yrs	US$165.15k	Veri yok
William McClellan	Independent Director	8.9yrs	US$169.49k	0.047% $ 270.3k
Adrian Park	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Talamini	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Santiago Horgan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jay Redan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Steve McCarus	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Marks	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
David Pacitti	Independent Director	5.4yrs	US$159.70k	0.0067% $ 38.9k

5.2yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: APEN's board of directors are considered experienced (5.2 years average tenure).

This company has been acquired

Apollo Endosurgery Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Apollo Endosurgery, Inc. Announces Board Changes

CEO, President & Director recently sold US$504k worth of stock

Recent updates

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Price target decreased to US$11.75

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Consensus forecasts updated

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus forecasts updated

Apollo Endosurgery, Inc. Announces Board Changes

Price target decreased to US$12.67

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold US$504k worth of stock

CEO, President & Director recently sold US$504k worth of stock

Chief Financial Officer recently bought US$219k worth of stock

Consensus forecasts updated

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Insider recently sold US$129k worth of stock

Price target increased to US$11.25

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

Apollo Endosurgery EPS beats by $0.05, beats on revenue

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Independent Chairman of the Board recently bought US$59k worth of stock

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

New 90-day high: US$6.10

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Insider recently bought US$86k worth of stock

Revenue beats expectations, earnings disappoint

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought US$146k worth of stock

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: US$4.86

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Assessing Apollo Endosurgery

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

New 90-day high: US$2.30

Analysts increase revenue estimates to US$40.2m

Third quarter 2020 earnings released: US$0.11 loss per share

Revenue beats expectations, earnings disappoint

Apollo Endosurgery EPS beats by $0.10, beats on revenue

New 90-day high: US$1.79

New 90-day low - US$1.31

First half earnings released